Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature
Omalizumab is a recombinant humanized monoclonal antibody that blocks the high-affinity Fc receptor of IgE. Omalizumab has been approved for the treatment of moderate to severe asthma; however, there is currently more and more data showing promising results in the management also of chronic urticari...
Saved in:
Main Authors: | Ilya Ivyanskiy (Author), Carsten Sand (Author), Simon Francis Thomsen (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2012-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predicting Response to Omalizumab in Chronic Urticaria Based on Biomarkers
by: Misbah Noshela Ghazanfar, et al.
Published: (2018) -
Position of omalizumab therapy in the treatment of spontaneous chronic urticaria. A case series and literature review
by: Aleksander Obtułowicz, et al.
Published: (2022) -
Omalizumab for Urticarial Vasculitis: Case Report and Review of the Literature
by: Misbah Nasheela Ghazanfar, et al.
Published: (2015) -
Omalizumab in the treatment of chronic spontaneous urticaria - literature review and own experience
by: Joanna Dawicka, et al.
Published: (2016) -
Omalizumab in treatment-resistant chronic spontaneous urticaria
by: Kiran V Godse
Published: (2011)